Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRF-1 antagonists GSK561679 and GW876008 on meal-induced cortisol responses in IBS
2007-000929-22Phase 2Terminated
- Sponsor
- GSK
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing GSK561679 period, GW876008 period and Placebo period (3 arms). Primary endpoint: Serum cortisol / ACTH and DHEA levels over time. Started May 2007; status: terminated.
02
Drugs
verucerfontemicerfont
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2007-000929-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000929-22.